These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34504010)

  • 1. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics.
    Ahmed L; Gupta P; Martin KP; Scheer JM; Nixon AE; Kumar S
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34504010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Embedding Dynamics in Intrinsic Physicochemical Profiles of Market-Stage Antibody-Based Biotherapeutics.
    Licari G; Martin KP; Crames M; Mozdzierz J; Marlow MS; Karow-Zwick AR; Kumar S; Bauer J
    Mol Pharm; 2023 Feb; 20(2):1096-1111. PubMed ID: 36573887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five computational developability guidelines for therapeutic antibody profiling.
    Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies.
    Jetha A; Thorsteinson N; Jmeian Y; Jeganathan A; Giblin P; Fransson J
    MAbs; 2018; 10(6):890-900. PubMed ID: 30110240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity.
    Lauer TM; Agrawal NJ; Chennamsetty N; Egodage K; Helk B; Trout BL
    J Pharm Sci; 2012 Jan; 101(1):102-15. PubMed ID: 21935950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies with Weakly Basic Isoelectric Points Minimize Trade-offs between Formulation and Physiological Colloidal Properties.
    Gupta P; Makowski EK; Kumar S; Zhang Y; Scheer JM; Tessier PM
    Mol Pharm; 2022 Mar; 19(3):775-787. PubMed ID: 35108018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues.
    Kaleli NE; Karadag M; Kalyoncu S
    Proteins; 2019 Jul; 87(7):607-618. PubMed ID: 30883916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics.
    Martin KP; Grimaldi C; Grempler R; Hansel S; Kumar S
    MAbs; 2023; 15(1):2191301. PubMed ID: 36998195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1.
    Douthwaite JA; Sridharan S; Huntington C; Hammersley J; Marwood R; Hakulinen JK; Ek M; Sjögren T; Rider D; Privezentzev C; Seaman JC; Cariuk P; Knights V; Young J; Wilkinson T; Sleeman M; Finch DK; Lowe DC; Vaughan TJ
    MAbs; 2015; 7(1):152-66. PubMed ID: 25484051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of monoclonal antibody viscosity using interpretable machine learning.
    Makowski EK; Chen HT; Wang T; Wu L; Huang J; Mock M; Underhill P; Pelegri-O'Day E; Maglalang E; Winters D; Tessier PM
    MAbs; 2024; 16(1):2303781. PubMed ID: 38475982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between the antigen and antibody is controlled by the constant domains: normal mode dynamics of the HEL-HyHEL-10 complex.
    Adachi M; Kurihara Y; Nojima H; Takeda-Shitaka M; Kamiya K; Umeyama H
    Protein Sci; 2003 Oct; 12(10):2125-31. PubMed ID: 14500870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How can we discover developable antibody-based biotherapeutics?
    Bauer J; Rajagopal N; Gupta P; Gupta P; Nixon AE; Kumar S
    Front Mol Biosci; 2023; 10():1221626. PubMed ID: 37609373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Prediction of Diffusion Interaction Parameter (k
    Tomar DS; Singh SK; Li L; Broulidakis MP; Kumar S
    Pharm Res; 2018 Aug; 35(10):193. PubMed ID: 30128780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Based Optimization of Antibody-Based Biotherapeutics for Improved Developability: A Practical Guide for Molecular Modelers.
    Thorsteinson N; Comeau SR; Kumar S
    Methods Mol Biol; 2023; 2552():219-235. PubMed ID: 36346594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An adapted consensus protein design strategy for identifying globally optimal biotherapeutics.
    Liu Y; Tsang K; Mays M; Hansen G; Chiecko J; Crames M; Wei Y; Zhou W; Fredrick C; Hu J; Liu D; Gebhard D; Huang ZF; Datar A; Kronkaitis A; Gueneva-Boucheva K; Seeliger D; Han F; Sen S; Kasturirangan S; Scheer JM; Nixon AE; Panavas T; Marlow MS; Kumar S
    MAbs; 2022; 14(1):2073632. PubMed ID: 35613320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.
    Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ
    MAbs; 2015; 7(1):212-30. PubMed ID: 25559441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling.
    Park E; Izadi S
    MAbs; 2024; 16(1):2362788. PubMed ID: 38853585
    [No Abstract]   [Full Text] [Related]  

  • 18. Developability assessment during the selection of novel therapeutic antibodies.
    Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H
    J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Models for Antibody Behavior in Hydrophobic Interaction Chromatography and in Self-Association.
    Hebditch M; Roche A; Curtis RA; Warwicker J
    J Pharm Sci; 2019 Apr; 108(4):1434-1441. PubMed ID: 30476509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
    Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
    MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.